RECEPTOR LOGIC/SANOFI PASTEUR DEVELOP TCR FOR VACCINE TESTS.Receptor Logic, Ltd., Austin, Texas, has announced a partnership with sanofi pasteur Sanofi pasteur is the vaccine division of sanofi-aventis Group. It is the largest company in the world devoted entirely to vaccines. History
In 2004, Aventis merged with and into Sanofi. The new sanofi-aventis Group became the world's 3rd largest pharmaceutical company. , the vaccines division of sanofi-aventis Group, to develop T Cell Receptor The T cell receptor or TCR is a molecule found on the surface of T lymphocytes (or T cells) that is generally responsible for recognizing antigens bound to major histocompatibility complex (MHC) molecules. Mimics (TCRm(tm)) for the validation and testing of sanofi pasteur vaccines. Under a collaborative research and exclusive license agreement, Receptor Logic will create custom TCRm in support of sanofi pasteur's vaccine programs. Receptor Logic is funded and managed by life sciences venture firm, Emergent Technologies, Inc. (ETI (Embed The Internet) An earlier consortium that was devoted to putting Web servers into microcontrollers used in embedded systems. Using a Web server enables access to the device via any Web browser. See Web server and microcontroller. ).
Tony Taylor, Emergent Technologies Senior Vice President, Strategic Planning Strategic planning is an organization's process of defining its strategy, or direction, and making decisions on allocating its resources to pursue this strategy, including its capital and people. , stated, "Receptor Logic has developed a powerful tool called 'T Cell Receptor Mimics (TCRm(tm))' aimed at measuring immune presentation. Sanofi pasteur's interest in this novel approach supports the potential value of this technology towards the development of vaccines and drugs in the future."
About Receptor Logic, Ltd.
Receptor Logic, Ltd. is a biopharmaceutical company specializing in high-quality antibodies that mimic the specificity of T Cell Receptors in the immune system immune system
Cells, cell products, organs, and structures of the body involved in the detection and destruction of foreign invaders, such as bacteria, viruses, and cancer cells. Immunity is based on the system's ability to launch a defense against such invaders. . These T Cell Receptor mimics (TCRm) offer valuable insight into how the immune system interacts with a diseased cell, yielding better immunology research, better clinical diagnostics, and better therapies such as monoclonal antibodies This is a list of monoclonal antibodies, antibodies which are clones of a single parent cell. When used as medications, the generic names end in -mab (see "Nomenclature of monoclonal antibodies"). and vaccines.
In 2004 Receptor Logic, Ltd. was awarded $2 million from the Advanced Technology Program (ATP ATP: see adenosine triphosphate.
in full adenosine triphosphate
Organic compound, substrate in many enzyme-catalyzed reactions (see catalysis) in the cells of animals, plants, and microorganisms. ) of the National Institute of Standards & Technology (NIST (National Institute of Standards & Technology, Washington, DC, www.nist.gov) The standards-defining agency of the U.S. government, formerly the National Bureau of Standards. It is one of three agencies that fall under the Technology Administration (www.technology. ) to fund development of a cancer profiling and immunotherapy platform targeting breast cancer. Receptor Logic, Ltd. is an Emergent Technologies Inc. (ETI) portfolio company, and ETI provides all management services. For more information, visit the company website www.receptorlogic.com.
About Emergent Technologies, Inc.
Emergent Technologies Inc. (ETI), founded in 1989 by Thomas A. Harlan, is a unique life sciences venture firm that forms and manages companies and funds that commercialize groundbreaking institutional and university-based technologies. ETI is a turnkey solution for converting university science into high return ventures. ETI works with regional economic development groups and universities to capitalize on the technology assets unique to their region. ETI is pioneering a unique business approach the firm describes as invention capital.
In addition to the traditional venture capital approach of raising and investing funds, ETI drives the selection and expansion of each investment's intellectual property, the key asset to most technology-based start-up companies.
For more informaton, call 321/591-1508 or visit http://www.etibio.com.